Newron Pharmaceuticals SpA - Company Profile

Powered by

All the data and insights you need on Newron Pharmaceuticals SpA in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Newron Pharmaceuticals SpA Strategy Report

  • Understand Newron Pharmaceuticals SpA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Newron Pharmaceuticals SpA: Overview

Select Item

Newron Pharmaceuticals SpA (Newron Pharmaceuticals) is a research-based biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed the product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newton's other products in the pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. It operates along with its subsidiaries in the UK, Switzerland, Sweden, and the US. Newron is headquartered in Bresso, Milan, Italy.

 Gain a 360-degree view of Newron Pharmaceuticals SpA and make more informed decisions for your business Gain a 360-degree view of Newron Pharmaceuticals SpA and make more informed decisions for your business Find out more
Headquarters Italy
Address Via Antonio Meucci 3, Bresso, 20091
Website www.newron.com
Telephone 39 02 6103461
No of Employees 23
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange NWRN (SWF)
Revenue (2022) $9.8M 48.6% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 7.3% (2022 vs 2021)
Market Cap* $148.6M
Net Profit Margin (2022) XYZ 37.6% (2022 vs 2021)
* As of and is in US$
View Newron Pharmaceuticals SpA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Newron Pharmaceuticals SpA premium industry data and analytics

70+

Clinical Trials

Determine Newron Pharmaceuticals SpA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Newron Pharmaceuticals SpA’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Newron Pharmaceuticals SpA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

14+

Pipeline Drugs

Identify which of Newron Pharmaceuticals SpA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products Brands
Marketed Product: Xadago
Xadago (Safinamide) - Parkinson’s Disease
Pipeline
XYZ
XYZ
XYZ
Understand Newron Pharmaceuticals SpA portfolio and identify potential areas for collaboration Understand Newron Pharmaceuticals SpA portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Newron Pharmaceuticals SpA Pharming Group NV Biofrontera AG Silence Therapeutics Plc AC Immune SA
Headquarters Italy Netherlands Germany United Kingdom Switzerland
City Bresso Leiden Leverkusen London Lausanne
State/Province - - Nordrhein-Westfalen England -
No. of Employees 23 415 91 116 133
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Ulrich Kostlin Chairman Executive Board 2013 -
Stefan Weber Director; Chief Executive Officer Executive Board 2012 -
Ravi Anand Chief Medical Officer Senior Management 2005 -
Roberto Galli Vice President - Finance Senior Management 2012 -
Marco Caremi Executive Vice President - Business Development Senior Management 2012 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Newron Pharmaceuticals SpA key executives to enhance your sales strategy Gain insight into Newron Pharmaceuticals SpA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Start of HubSpot Embed Code End of HubSpot Embed Code